TAKEDA PHARMACEUTICAL COMPANY LIMITED · 武田薬品工業株式会社
| Revenue | ¥4.51T |
|---|---|
| Operating income | ¥6.2B |
| Net income | ¥-152.4B |
| Free cash flow | ¥1.04T |
| Operating margin | 0.1% |
| Net margin | -3.4% |
| Return on equity | -2.1% |
| Period | 2026 |
OpenFilings analyst
Our analyst
Agentic read of the latest earnings call — recommendation updates when we process a new transcript. Research synthesis, not investment advice.
Promising catalysts are offset by competitive uncertainty, unproven clinical durability and diagnostic or commercial execution risk.
Takeda’s R&D portfolio offers multiple high-upside catalysts, including oveporexton Phase III data in 2025, elritercept’s 50%+ transfusion-independence rate in RS-positive MDS and 134-week median response duration, and fazirsiran’s 94% reduction in liver protein burden. However, most assets remain pre-commercial and the Q&A exposed material execution and competitive risks: zaso lacks planned head-to-head trials against IL-17/TNF agents, mezagitamab’s 55% UPCR reduction trails competing benchmarks, and fazirsiran depends on early diagnosis and a long surrogate-endpoint trial. The pipeline is attractive, but not sufficiently de-risked for an aggressive post-call purchase.
- Oveporexton
- Zasocitinib
- Rusfertide
- Mezagitamab
- Fazirsiran
- Elritercept
Near term
Oveporexton Phase III readout in 2025 is the clearest near-term valuation catalyst; management claims normalization across sleepiness, cognition and other symptoms, but the twice-daily regimen remains a commercial usability question.
Zasocitinib Phase III psoriasis data are expected in approximately 12 months; management expects strong efficacy, but acknowledged the market is hypercompetitive and has no plans for head-to-head trials against IL-17 or TNF-alpha in psoriatic arthritis.
Rusfertide Phase III data are expected next quarter, with secondary malignancies and myelosuppression still important safety watchpoints after 11 skin cancers in the extension study.
Phase III starts for mezagitamab in IgA nephropathy and ITP are important catalysts, but the IgAN dosing schedule was not yet finalized.
Longer term
Oveporexton and fazirsiran could address largely underdiagnosed or poorly treated markets, potentially allowing Takeda to shape demand rather than merely take share.
Elritercept has a broad potential label across low-risk MDS, myelofibrosis and other anemia-associated diseases, but its efficacy claims are based on Phase II data and must translate into registrational trials.
Mezagitamab’s CD38 mechanism and potential treatment holidays could differentiate it if sustained kidney-function preservation is confirmed, though comparative efficacy and infection risk remain unresolved.
Takeda’s external-deal-heavy pipeline can replenish growth, but returns depend on disciplined licensing economics and improved R&D productivity; management conceded productivity must increase over the next five to 10 years.
Zasocitinib’s commercial opportunity depends on expanding oral use in psoriasis and proving sufficient efficacy against established biologic standards, not simply outperforming SOTYKTU.
Red flags
Management did not directly address whether mezagitamab’s 55% UPCR reduction is competitive, instead emphasizing stable eGFR from a small proof-of-concept study; Phase III dosing and design were still being finalized.
Mezagitamab infection risk was answered with limited clinical exposure and a theoretical selectivity advantage; management explicitly said additional safety data are needed.
Rusfertide’s 11 skin cancers were attributed to disease and hydroxyurea risk factors, but Takeda has not received the final two-year rat carcinogenicity report and long-term human causality remains unresolved.
Fazirsiran’s Phase III primary endpoint is a one-point fibrosis reduction at week 106, while the commercial thesis depends on earlier diagnosis that management admitted will not be in place at launch.
Zasocitinib enters a crowded IL-23 market, and management declined to commit to head-to-head trials against IL-17 or TNF-alpha in psoriatic arthritis.
The company’s headline $10 billion-$20 billion opportunity is explicitly risk-unadjusted, while four of the six highlighted assets are licensed rather than internally discovered.
OpenFilings analyst view from primary-source filings and earnings calls — not investment advice.
From latest ANNUAL · 2017-06-29
- Current Ratio Low
Red flags
- Current Ratio Low — Current ratio 0.76
Upcoming earnings
Earnings transcripts
- Motley Fool
Takeda (TAK) Q1 2026 Earnings Call Transcript
TAKEDA PHARMACEUTICAL COMPANY LIMITED
- Issuer webcast
Webcast Go to https://www.irwebcasting.com/20260329/2/index.html
TAKEDA PHARMACEUTICAL COMPANY LIMITED
- Issuer webcast
Webcast Go to https://www.irwebcasting.com/20250908/2/index.html
TAKEDA PHARMACEUTICAL COMPANY LIMITED
- Issuer webcast
Webcast Go to https://www.irwebcasting.com/20250602/2/index.html
TAKEDA PHARMACEUTICAL COMPANY LIMITED
- Issuer IR
Takeda RD Day 12 2024 Transcript vF
TAKEDA PHARMACEUTICAL COMPANY LIMITED
- Issuer webcast
Webcast Go to https://www.irwebcasting.com/20241213/3/
TAKEDA PHARMACEUTICAL COMPANY LIMITED